Journal of Cancer Immunology and Therapy is an academic journal and aims to publish most complete and reliable source of information on the discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in all areas of the field and making them freely available through online without any restrictions or any other subscriptions to researchers worldwide. The journal selects the articles to be published with a single bind, peer review system, following the practices of good scholarly journals. It supports the open access policy of making scientific research accessible to one and all. 

We are sharing one of the most cited article from our journal. Editorial entitled “Immunotherapy in breast cancer: where we stand?” well written by Dr. Rosalin Mishra.

Several cellular signaling mechanisms including altered immune, inflammatory and oxidative stress response determine the fate of a breast tumor and its metastasis. Despite the development of different effective therapies over past several decades, breast cancer accounts for 14% of cancer deaths and is one of the major causes of cancer related deaths in united states and worldwide. Conventional therapies including surgery, chemo-, radiation- or targeted- therapies including endocrine therapy have initial promising results in treating patients with breast cancer, however fail to completely eradicate breast cancer and curtail its distant metastasis in several cases. This is attributed to the heterogeneous nature of the disease, tumor cell plasticity, expression of different hormone receptors, inter- and intra-tumor heterogeneity associated with different patients. The chemo- and radiation therapies are associated with toxicities and several side effects and have modest improvement in the overall survival in many cases of breast cancer patients. Continuous exposure of cancer cells to radiations over a prolonged period transforms the nearby normal cells to neoplastic ones. Multidrug resistance (MDR) remains the main impediment in treatment of patients with the advanced disease using targeted therapies. Immunotherapy is the new promising alternative treatment approach because of it relatively low toxicity effects and ability of the immune cells to identify and destroy cancer cells. Several immunotherapy modalities including immune checkpoint inhibitors, bispecific antibodies, cancer vaccines and stimulatory molecule agonists are in various phases of clinical trials which have generated mixed results in patients with breast cancer.

To read more: https://www.alliedacademies.org/articles/immunotherapy-in-breast-cancer-where-we-stand-10851.html

Manuscripts related to the above relevant topics can be submitted to the Journal through online or as an attachment to the E-mail: cancerimmunol@eclinicalsci.com. High quality submissions are expected to maintain the standard of the journal

Media Contact,

Shelley Brown

Editorial Team

Journal of Cancer Immunology and Therapy

Email: cancerimmunol@eclinicalsci.com

WhatsApp: +1-97-333-4405